Shineco (NASDAQ:SISI – Get Free Report) and TherapeuticsMD (NASDAQ:TXMD – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings.
Analyst Ratings
This is a summary of current recommendations and price targets for Shineco and TherapeuticsMD, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Shineco | 1 | 0 | 0 | 0 | 1.00 |
| TherapeuticsMD | 1 | 0 | 0 | 0 | 1.00 |
Valuation & Earnings
This table compares Shineco and TherapeuticsMD”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Shineco | $9.60 million | 0.00 | -$22.45 million | ($204.00) | -0.00 |
| TherapeuticsMD | $3.27 million | 7.22 | -$570,000.00 | $0.02 | 102.00 |
TherapeuticsMD has lower revenue, but higher earnings than Shineco. Shineco is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Shineco and TherapeuticsMD’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Shineco | -380.55% | -79.89% | -33.01% |
| TherapeuticsMD | -6.64% | -1.09% | -0.78% |
Risk and Volatility
Shineco has a beta of -1.76, meaning that its stock price is 276% less volatile than the S&P 500. Comparatively, TherapeuticsMD has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.
Institutional & Insider Ownership
4.1% of Shineco shares are held by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are held by institutional investors. 0.0% of Shineco shares are held by company insiders. Comparatively, 1.7% of TherapeuticsMD shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
TherapeuticsMD beats Shineco on 10 of the 11 factors compared between the two stocks.
About Shineco
Shineco, Inc., through its subsidiaries, processes and distributes agricultural produce. It also engages in the growing and cultivation of mulberry trees and silkworm cocoons; distribution of fruit business; and processing and distribution of silk and silk fabrics, as well as other by-products. The company was incorporated in 1997 and is headquartered in Beijing, the People's Republic of China.
About TherapeuticsMD
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Receive News & Ratings for Shineco Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shineco and related companies with MarketBeat.com's FREE daily email newsletter.
